Skip to main content
. 2020 Aug 4;38(30):3528–3537. doi: 10.1200/JCO.20.00799

FIG 2.

FIG 2.

Kaplan-Meier estimates of investigator-assessed progression-free survival (PFS) for subgroup analyses based on (A) surgery timing, (B) residual macroscopic disease status, (C) patients with stage III disease who underwent upfront surgery and had no gross residual disease, (D) response after platinum-based chemotherapy at baseline, and (E) BRCA mutation status. CR, complete response; HR, hazard ratio; NR, not reached; PR, partial response.